2023 World Conference on Lung Cancer (Posters)-EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1

EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1 - PDF(Abstract)

Back to course

Pdf Summary

The study focused on the comparison of treatment options for metastatic non-small cell lung cancer (NSCLC) patients who had previously received platinum-based doublets and immune checkpoint blockade. The standard treatment after progression on these therapies is Docetaxel (Doc) with or without Ramucirumab (Ram), but its clinical benefit is short-lived and associated with toxicity. The study aimed to investigate whether cancer gene mutation status impacts the benefit from Doc and whether platinum-taxane regimens offer better efficacy.<br /><br />The researchers analyzed data from the MD Anderson GEMINI database and an external cohort from Mayo Clinic. They included factors such as age, gender, histology, performance status, metastatic sites, cancer gene mutation status, and prior treatment history for analyses of progression-free survival (PFS) and overall survival (OS).<br /><br />Among the patients treated with Doc/-Ram, the median PFS was 3.8 months and the median OS was 8.4 months. Female gender and ECOG performance status of 0-1 were associated with significantly longer PFS and OS. Cancer gene mutation status and PD-L1 level were not associated with PFS or OS. The platinum-taxane regimens had significantly longer PFS compared to Doc/-Ram.<br /><br />In conclusion, the clinical benefit from Doc/-Ram in patients with metastatic NSCLC who progressed on platinum-doublets and immune checkpoint blockade is not associated with cancer gene mutation status. Platinum-taxane regimens may offer superior benefit in this patient population. These findings provide valuable insights into the treatment options for metastatic NSCLC patients who have exhausted previous therapies.

Asset Subtitle

Kang Qin

Meta Tag

Speaker Kang Qin

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

metastatic non-small cell lung cancer

NSCLC

treatment options

platinum-based doublets

immune checkpoint blockade

Docetaxel

Ramucirumab

cancer gene mutation status

platinum-taxane regimens

clinical benefit